Recherches "plusieurs pathologies"
EXPRESS
Low level of genomic alteration to predict exceptional and unexpected response to targeted thÚrapies in patients with solid tumors.;EXPRESS : EXcePtional RESponSe
Paris
CHRISTOPHE LE TOURNEAU
Prostate
ARASENS
A randomized, double·blind, placebo·controlled Phase III study of ODM·201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone·sensitive prostate cancer.
Paris
PHILIPPE BEUZEBOC
Prostate
CARD (LPS14201)
A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD).
Paris
PHILIPPE BEUZEBOC
Prostate
PEACE 1 (GETUG-AFU 21)
A Prospective Randomised Phase III Study of Androgen Deprivation Therapy (+/- Docetaxel) With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-naïve Prostate Cancer.
Paris
FRANCESCO RICCI
Sein métastatique HER2+
HER2CLIMB (ONT-380-206)
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Paris
FRANCESCO RICCI
Sein métastatique HER2+
SOPHIA (CP-MGAH22-04)
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment.
Paris, Saint-Cloud
FRANCESCO RICCI, ETIENNE BRAIN
Recherches "plusieurs pathologies"
CA209-848
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Paris
EMANUELA ROMANO